Collegium Pharma (NASDAQ: COLL) reported Q4 EPS of ($0.73), $1.77 worse than the analyst estimate of $1.04. Revenue for the quarter came in at $27.36 million versus the consensus estimate of $81.61 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.